A strategic partnership has been announced between biopharmaceutical contract services company, KBI Biopharma, and provider of formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics, ReForm Biologics.
Strategic acquisition
Through this collaboration, KBI will provide services to ReForm to further develop and validate its biologic formulation platform while also gaining access to ReForm’s proprietary technology. Reform will maintain the ability to use its formulation technologies directly with its pharmaceutical and biotechnology partners. Financial terms of the agreement were not disclosed. Although, as a part of the agreement, KBI has made an equity investment in ReForm Biologics.
“We are very excited to collaborate with ReForm and leverage their enabling formulation technology to advance the programs of our client partners,” said Tim Kelly PhD, president and CEO of KBI. “KBI has a long-standing track record of leadership in the formulation of biologics, and ReForm’s unique technology will help us address some of the biggest challenges in protein formulation. Together, KBI and ReForm will help transform our clients’ most innovative pipeline discoveries into viable commercial products to treat patients.”
“This collaboration brings together ReForm’s innovative formulation platforms with KBI’s deep industry experience and global customer base,” added John M. Sorvillo PhD, chief executive officer at ReForm. “Access to KBI’s services and customers will allow us to advance our technologies more rapidly and generate additional revenues for both companies. We are pleased to have KBI as a shareholder and strategic partner as we expand our transformative platforms for biotherapeutic formulations, for the benefit of patients.”
